Austria HIV Therapeutics Market Analysis Report [2022-30]

Austria HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Austria HIV therapeutics market will reach a value of $xx Mn from $55.04 Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Polymun, Astria Therapeutics, and Gilead Sciences. The market is driven by government policies and non-governmental organizations’ initiatives for the management of HIV infections in the country. The HIV therapeutics market in Austria is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10ATPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Austria AUTHOR: Dr. Vishwa Modhia

Buy Now

Austria HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Austria HIV therapeutics market will reach a value of $xx Mn from $55.04 Mn in 2022, growing at a CAGR of xx% during 2022-2030.

The Republic of Austria is a landlocked country in Central Europe. The number of HIV/AIDS-related deaths in Austria will reach 100 in 2020, according to the most recent WHO data. With an age-adjusted death rate of 0.32 per 100,000 people, Austria is ranked 133rd globally. In Austria, the adult HIV/AIDS prevalence rate in 2021 was 0.1%.

The second-lowest number of new cases of HIV (human immunodeficiency virus) in the time period given was 175, which occurred in Austria in 2021. After reaching a peak of 376 cases in 2012, HIV cases in Austria have generally decreased in recent years. In 2019, Austria's GDP was 11.5% devoted to healthcare.

Market Growth Drivers Analysis

Market Dynamics

The cost of pharmaceuticals per capita in Austria is among the highest in the world. In 2021, pharmaceutical sales are estimated to have reached $9.2 Bn or $1,033 per capita, around 15% of Austria’s $61.5 Bn total healthcare spending. By requiring mandatory employer and employee contributions, Austria's national health insurance program covers 99% of the population. An alliance of HIV/AIDS organizations in Austria published a position paper in November 2021 advocating for the criminal code's de-stigmatization of HIV. These elements may stimulate the Austrian market for HIV therapeutics.

Market Restraints

Despite the availability of antiretroviral drugs in Austria, there may still be some patients who face difficulties in accessing these drugs due to issues such as limited availability at certain hospitals or pharmacies. The use of antiretroviral drugs can be associated with adverse side effects, which can impact patient adherence to treatment.

Competitive Landscape

Key Players

Polymun (AUT)
Astria Therapeutics (AUT)
Gilead Sciences (AUT)
ViiV Healthcare
Bristol Myers Squibb
Roche
Merck
Pfizer
AstraZeneca
GlaxoSmithKline

Healthcare Regulations and Reimbursement Policies

The Austrian Medicines Agency (AGES), which is a division of the Austrian Federal Office for Safety in Healthcare (BASG), is the principal regulatory body for antiretroviral medications used to treat HIV in Austria. In Austria, AGES is in charge of pharmaceutical product approval, vigilance, and monitoring, including for antiretroviral medications. The Austrian Federal Office for Safety in Healthcare (BASG) and the Austrian Federal Ministry of Health collaborate with AGES to determine which antiretroviral medications are eligible for reimbursement by the statutory health insurance system.

In Austria, the statutory healthcare system is primarily responsible for paying for antiretroviral medications used to treat HIV. Those with HIV who are enrolled in the health insurance program are covered under this system for the cost of medications, though there may be limitations on the kinds of medications that qualify for reimbursement. Antiretroviral medications must be accepted by the Austrian Medicines Agency (AGES) and listed on the Austrian Positive List, a list of medications covered by the statutory health insurance system and therefore eligible for reimbursement.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.